Saxagliptin (Onglyza) is an anti-diabetic drug of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. DPP-4 is an enzyme that breaks down incretin hormones. Increasing the level of these hormones in the body rise insulin production in response to meals and decreasing the rate of gluconeogenesis in the liver. The PheWeb instance associated to this project is available at https://statgen.org/pheweb/saxa/.
The COLchicine Cardiovascular Outcomes Trial (COLCOT) is the study of the Pharmacogenomics of the Efficacy and Safety of Colchicine (doi: 10.1161/CIRCGEN.120.003183). The PheWeb instance associated to this project is available at https://statgen.org/pheweb/colcot/.
A genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial was performed (doi: 10.1038/s41598-021-90365-6). The PheWeb instance associated to this project is available at https://statgen.org/pheweb/colcorona/.
The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomised, double-blind clinical trials comparing candesartan with placebo in patients with heart failure (HF) categorised according to left ventricular ejection fraction and tolerability to an ACE inhibitor. We conducted a pharmacogenomic study of the CHARM studies to identify genetic predictors of heart failure progression and the efficacy and safety of treatment with candesartan (doi: 10.1002/ehf2.14026). The PheWeb instance associated to this project is available at https://pheweb.statgen.org/charm/.